Bristol-Myers Squibb | BMY - Ebitda


Bristol-Myers Squibb reported $2.88B in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Abbott USD 3.27B 178M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
J&J USD 7.19B 2.32B Dec/2025
Medtronic USD 2.81B 119M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Sanofi EUR 5.66B 3.77B Sep/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Zoetis USD 939M 101M Dec/2025